Exploring combinations of aminoglycoside antibiotics to fight resistant bacteria
Structural, functional, and microbiological exploration toward synergistic dual aminoglycoside combinations
This study is looking at how pairing certain antibiotics can make them work better against tough bacteria that don't respond to regular treatments, with the hope of finding safer and more effective options for people dealing with these stubborn infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11057157 on NIH RePORTER |
What this research studies
This research investigates the use of dual combinations of aminoglycoside antibiotics to enhance their effectiveness against multidrug-resistant Gram-negative bacteria. By examining how these antibiotics interact with different sites on the bacterial ribosome, the study aims to identify combinations that can kill bacteria more effectively while reducing the risk of resistance and toxicity. The approach involves laboratory assays using animal models to test the bactericidal effects of these combinations. If successful, this research could lead to improved treatment options for infections caused by resistant pathogens.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients with infections caused by multidrug-resistant Gram-negative bacteria.
Not a fit: Patients with infections caused by bacteria that are not resistant to antibiotics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new, more effective treatment options for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown that synergistic antibiotic combinations can be effective, but this specific approach using dual aminoglycoside combinations is relatively novel.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Bulman, Zackery P. — University of Illinois at Chicago
- Study coordinator: Bulman, Zackery P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.